Distinguished in NUT Carcinoma

Dr. John F. Hilton

Hematology Oncology
450 Brookline Ave, 
Boston, MA 
Distinguished in NUT Carcinoma
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Hilton is a Hematologist Oncology provider in Boston, Massachusetts. Dr. Hilton is rated as a Distinguished provider by MediFind in the treatment of NUT Carcinoma. His top areas of expertise are Febrile Neutropenia, Breast Cancer, NUT Carcinoma, and Agranulocytosis.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of NUT Carcinoma.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer (REaCT-Wellness)
A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer (REaCT-Wellness)
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Other
Study Phase: Phase 4
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Large-scale Longitudinal Oncology Registry
A Large-scale Longitudinal Oncology Registry
Enrollment Status: Suspended
Publish Date: February 04, 2025
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy
99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy
Enrollment Status: Terminated
Publish Date: December 11, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

103 Total Publications

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.
REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.
Journal: JNCI cancer spectrum
Published: May 22, 2025
Similar Doctors
Elite in NUT Carcinoma
Dr. James E. Bradner
Hematology Oncology
Elite in NUT Carcinoma
Dr. James E. Bradner
Hematology Oncology
44 Binney St, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-632-6629
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Bradner is a Hematologist Oncology provider in Boston, Massachusetts. Dr. Bradner is rated as a Distinguished provider by MediFind in the treatment of NUT Carcinoma. His top areas of expertise are NUT Carcinoma, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Acute Myeloid Leukemia (AML). Dr. Bradner is currently accepting new patients.

Elite in NUT Carcinoma
Dr. Glenn J. Hanna
Hematology Oncology | Hematology | Oncology
Elite in NUT Carcinoma
Dr. Glenn J. Hanna
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Glenn Hanna is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Hanna is rated as an Elite provider by MediFind in the treatment of NUT Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, and NUT Carcinoma. Dr. Hanna is currently accepting new patients.

Advanced in NUT Carcinoma
Dr. David A. Barbie
Hematology Oncology | Oncology
Advanced in NUT Carcinoma
Dr. David A. Barbie
Hematology Oncology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Barbie is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Barbie is rated as a Distinguished provider by MediFind in the treatment of NUT Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Barbie is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hilton's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile